Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million Morefool.comVericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.
Why This Tech Fund Made a $5.8 Million Bet on an AI Chip Stock Up Nearly 200% Post-IPOfool.comAmbiq Micro designs ultra-low-power chips for wearables, IoT, and edge AI, targeting energy efficiency in connected devices.
This AI Semiconductor Stock Beat the S&P 500 by 9 Points. A Fund Just Exited Completelyfool.comAmbarella delivers advanced semiconductor solutions for video, AI, and computer vision across automotive, security, and robotics markets.
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Positionfool.comThis clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drugfool.comAlumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Is Paymentus Stock a Buy After Palisades Investment Partners Increased Its Stake By $6 Million?fool.comPaymentus delivers cloud-based bill payment technology to major enterprises across regulated and service-intensive industries.
Is Amprius Technologies Stock a Buy After Palisades Investment Partners Initiated a Position Worth $4.8 Million?fool.comAmprius Technologies manufactures silicon nanowire lithium-ion batteries for aerospace, defense, and electric mobility markets.
Palisades Investment Partners Initiated a Position in SkyWater Technology Stock. What Does This Mean for Investors?fool.comSkyWater Technology delivers custom semiconductor solutions for sectors including aerospace, automotive, and industrial IoT.
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investmentfool.comViking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Dropfool.comThis biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Millionfool.comNurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%fool.comThis clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Yearfool.comThis clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025fool.comKrystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%fool.comScholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimismstocktwits.comJefferies’ new price target represents a potential upside of about 34% from the stock’s closing price on Friday.
